Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 4
Submit an article Journal homepage
1,638
Views
28
CrossRef citations to date
0
Altmetric
Author's View

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

Huafeng Wei International Joint Cancer Institute; Second Military Medical University; Shanghai, China; School of Pharmacy; Liaocheng University; Liaocheng, China; State Key Laboratory of Antibody Medicine & Targeting Therapy and Shanghai Key Laboratory of Cell Engineering & Antibody; Shanghai, ChinaCorrespondence[email protected] [email protected]
,
Likun Zhao School of Bioscience and Bioengineering; South China University of Technology; Guangzhou, China
,
Ingegerd Hellstrom Department of Pathology; Harborview Medical Center; University of Washington; Seattle, WA USA
,
Karl Erik Hellstrom Department of Pathology; Harborview Medical Center; University of Washington; Seattle, WA USA
&
Yajun Guo International Joint Cancer Institute; Second Military Medical University; Shanghai, China; School of Pharmacy; Liaocheng University; Liaocheng, China; State Key Laboratory of Antibody Medicine & Targeting Therapy and Shanghai Key Laboratory of Cell Engineering & Antibody; Shanghai, China; School of Bioscience and Bioengineering; South China University of Technology; Guangzhou, ChinaCorrespondence[email protected] [email protected]
Article: e28248 | Received 12 Feb 2014, Accepted 15 Feb 2014, Published online: 28 Mar 2014

References

  • Mantia-Smaldone GM, Corr B, Chu CS. Immunotherapy in ovarian cancer. Hum Vaccin Immunother 2012; 8:1179 - 91; http://dx.doi.org/10.4161/hv.20738; PMID: 22906947
  • Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013; 36:248 - 57; http://dx.doi.org/10.1097/CJI.0b013e3182943549; PMID: 23603859
  • Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013; 8:e84927; http://dx.doi.org/10.1371/journal.pone.0084927; PMID: 24367702
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1 - 10; http://dx.doi.org/10.1016/j.immuni.2013.07.012; PMID: 23890059
  • Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61 - 73; http://dx.doi.org/10.1016/j.immuni.2013.07.005; PMID: 23890064
  • Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997 - 1008; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214; PMID: 23460531
  • Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550; PMID: 23975756
  • Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210; PMID: 22570253
  • Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508 - 16; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008; PMID: 21074066
  • Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, Jaffar J, Hellstrom I, Liu J, Hellstrom KE. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 2010; 132:6906 - 7; http://dx.doi.org/10.1021/ja102414t; PMID: 20433206

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.